Sanuwave Health (NASDAQ:SNWV) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Key Points

• Sanuwave Health reported earnings of $0.01 per share for the quarter, beating the consensus estimate of ($0.09) by $0.10.
• The company's stock rose $5.44 during midday trading, reaching a price of $39.76, with a market cap of $340.70 million.
• Geode Capital Management acquired a new stake in Sanuwave Health, buying 157,727 shares, which represents approximately 1.84% of the company.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) issued its quarterly earnings results on Friday. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10, Zacks reports. The firm had revenue of $10.16 million during the quarter, compared to the consensus estimate of $10.14 million. Sanuwave Health updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Sanuwave Health Stock Performance

SNWV traded up $0.47 during trading on Wednesday, reaching $42.17. 3,486 shares of the company were exchanged, compared to its average volume of 52,310. The firm has a market capitalization of $361.40 million, a PE ratio of -5.11 and a beta of 1.29. The business's 50 day moving average price is $34.10. Sanuwave Health has a 52 week low of $5.21 and a 52 week high of $46.58.

Insiders Place Their Bets

In other Sanuwave Health news, insider Iulian Cioanta sold 3,639 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $31.60, for a total transaction of $114,992.40. Following the completion of the transaction, the insider owned 41 shares in the company, valued at approximately $1,295.60. The trade was a 98.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Peter Stegagno sold 1,862 shares of the business's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $27.71, for a total value of $51,596.02. Following the transaction, the chief operating officer owned 2,032 shares of the company's stock, valued at $56,306.72. This trade represents a 47.82% decrease in their position. The disclosure for this sale can be found here. 14.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in Sanuwave Health during the 2nd quarter worth $5,184,000. Goldman Sachs Group Inc. acquired a new position in Sanuwave Health during the 1st quarter worth $337,000. Rhumbline Advisers acquired a new position in Sanuwave Health during the 2nd quarter worth $211,000. JPMorgan Chase & Co. acquired a new position in Sanuwave Health during the 2nd quarter worth $109,000. Finally, Legal & General Group Plc acquired a new position in Sanuwave Health during the 2nd quarter worth $26,000. Institutional investors and hedge funds own 42.53% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wall Street Zen upgraded Sanuwave Health from a "hold" rating to a "buy" rating in a research note on Saturday. Roth Capital assumed coverage on Sanuwave Health in a research note on Tuesday, July 29th. They set a "buy" rating and a $49.00 price objective for the company.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.